Page 3 - Mark Lanasa News Today

Tislelizumab demonstrated non-inferiority for overall survival and favorable safety profile versus sorafenib in global Phase 3 trialAdditional poster presentations show breadth of tislelizumab global clinical development program as single-agent treatment and in combinationCAMBRIDGE, Mass. & BASEL, Switzerland & BEIJ...

09.08.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the global ... Seite 1

27.04.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the ... Seite 1

Statistically significant and clinically meaningful improvement in overall survival achieved for tislelizumab and chemotherapy compared to placebo and chemotherapy Safety profile for the

Tislelizumab is now approved for eight indications in China BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative

Results from subanalyses of RATIONALE-303 and -304 add to the growing body of data on tislelizumab as a potential treatment for non-small cell lung cancer Biomarker studies shed light on patient

Results from subanalyses of RATIONALE-303 and -304 add to the growing body of data on tislelizumab as a potential treatment for non-small cell lung cancerBiomarker studies shed light on patient characteristics driving improved response to PD-(L)1 inhibitorsCAMBRIDGE, Mass. & BEIJING & BASEL, Switzerland--(BUSINESS W...

Tislelizumab is now approved in seven indications in China BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative